[HTML][HTML] Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature …
The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.
L Gopcsa, M Réti, H Andrikovics, I Bobek, G Bekő… - Geroscience, 2023 - europepmc.org
The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review
L Gopcsa, M Réti, H Andrikovics, I Bobek… - …, 2024 - pubmed.ncbi.nlm.nih.gov
The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
[PDF][PDF] Effective virus‑specific T‑cell therapy for high‑risk SARS‑CoV‑2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature
L Gopcsa, M Réti, H Andrikovics, I Bobek, G Bekő… - 2023 - scienceopen.com
The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
[HTML][HTML] Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature …
L Gopcsa, M Réti, H Andrikovics, I Bobek, G Bekő… - …, 2024 - ncbi.nlm.nih.gov
The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.
L Gopcsa, M Réti, H Andrikovics, I Bobek, G Bekő… - Geroscience, 2023 - europepmc.org
The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …